Drug Trial Radar · NCT06346197
Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas
Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
132
Planned (sponsor's estimate)
Start
Dec 8, 2025
Primary completion
May 15, 2028
Study completion May 15, 2028
Sponsor
- Lead sponsor
- Centre Leon BerardAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Agenus Inc.
- First posted
- Apr 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
CIME is a multicenter, randomised, comparative, open-label phase III study aiming to compare the survival of patients suffering from MSI-H/dMMR locally advanced or metastatic oeasogastric adenocarcinoma treated by a bi-immunotherapy (experimental arm) versus standard current treatment (FOLFOX/XELOX + nivolumab : standard arm).
Conditions
- Gastric Cancer
- MSI-H
- Metastatic Cancer
- Advanced Cancer
Interventions
BalstilimabDrug
Balstilimab: 240mg, IV, Q2W, until disease progression, unacceptable toxicity, patient or investigator decision or up to 2 years.
BotensilimabDrug
Botensilimab: 75mg, IV for up to 4 doses, Q6W until disease progression, unacceptable toxicity, patient or investigator decision or up to 2 years.
Folfox ProtocolDrug
oxaliplatin 85 mg/m2 , leucovorin 400 mg/m2 , and fluorouracil 400 mg/m2 administered IV on Day 1 of each treatment cycle, and fluorouracil 1200 mg/m2 IV continuous infusion over 24 hours daily or per local standard on Days 1 and 2 of each treatment cycle, every 2 weeks.Treatment is recommended until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.
XELOXDrug
Oxaliplatin 130mg/m² IV on Day 1 of each treatment cycle + capecitabine 1000mg/m² orally twice daily on Days 1 to 14 of each treatment cycle, every 3 weeks. Treatment is recommended until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.
NivolumabDrug
240mg, IV, Q2. Treatment is recommended until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Survival of patientsTime frame: at least 2 years
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
CHU de Brest
Brest, France · Recruiting
CHU de Clermont-Ferrand
Clermont-Ferrand, France · Recruiting
Centre Léon Bérard
Lyon, France · Recruiting
Hôpital Privé Jean Mermoz
Lyon, France · Recruiting
Institut Paoli Calmettes
Marseille, France · Recruiting
Institut Mutualiste Montsouris
Paris, France · Recruiting
CHU de Poitiers
Poitiers, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.